Issue 3/2020
Content (15 Articles)
Impact of the COVID-19 Outbreak on the Management of Patients with Cancer
Eric Raymond, Catherine Thieblemont, Severine Alran, Sandrine Faivre
MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside
Margherita Ratti, Andrea Lampis, Michele Ghidini, Massimiliano Salati, Milko B. Mirchev, Nicola Valeri, Jens C. Hahne
Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review
Aye Myat Thi, Sandar Tin Tin, Mark McKeage, J. Mark Elwood
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
Simon Chowdhury, Anders Bjartell, Nicolaas Lumen, Pablo Maroto, Thomas Paiss, Francisco Gomez-Veiga, Alison Birtle, Gero Kramer, Ewa Kalinka, Dominique Spaëth, Susan Feyerabend, Vsevolod Matveev, Florence Lefresne, Martin Lukac, Robert Wapenaar, Luis Costa
Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy
Takanobu Yamada, Tsutomu Hayashi, Yasuhiro Inokuchi, Kimihiro Hayashi, Hayato Watanabe, Keisuke Komori, Kazuki Kano, Yota Shimoda, Hirohito Fujikawa, Manabu Shiozawa, Soichiro Morinaga, Yasushi Rino, Munetaka Masuda, Takashi Ogata, Takashi Oshima
Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors
Vincenzo Formica, Cristina Morelli, Anna Patrikidou, Carmen Murias, Sabeeh Butt, Antonella Nardecchia, Jessica Lucchetti, Nicola Renzi, Kai-Keen Shiu, Mario Roselli, Hendrik-Tobias Arkenau
Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis
Ya Chen, Shuyuan Wang, Bo Zhang, Yiming Zhao, Lele Zhang, Minjuan Hu, Wei Zhang, Baohui Han
Impact of Serum γ-Glutamyltransferase on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy
Kosuke Takemura, Takeshi Yuasa, Kentaro Inamura, Gulanbar Amori, Fumitaka Koga, Philip G. Board, Junji Yonese
Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations
Haiyan Xu, Weihua Li, Guangjian Yang, Junling Li, Lu Yang, Fei Xu, Yaning Yang, Jianming Ying, Yan Wang
Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas
Shengnan Ding, Xia Mao, Yang Cao, Na Wang, Hao Xu, Jianfeng Zhou
Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer
Jörg Hänze, Moritz Wegner, Elfriede Noessner, Rainer Hofmann, Axel Hegele
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
Domenica Lorusso, Jesús García-Donas, Jalid Sehouli, Florence Joly
Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review
An-Katrien Seghers, Pieter-Jan Cuyle, Eric Van Cutsem
Authors’ Reply to Yusuf Ziya Sener: “Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study”
Jwa Hoon Kim, Jeong Eun Kim, Yong Sang Hong